Anti-Cancer Everolimus Purity Everolimus Powder Raw Powder Everolimus

Product Details
Customization: Available
Powder: Yes
Customized: Customized
Still deciding? Get samples of $ !
Request Sample
Diamond Member Since 2021

Suppliers with verified business licenses

Audited Supplier

Audited by an independent third-party inspection agency

Management System Certification
ISO 9001, ISO 14001, GMP, HACCP
  • Anti-Cancer Everolimus Purity Everolimus Powder Raw Powder Everolimus
  • Anti-Cancer Everolimus Purity Everolimus Powder Raw Powder Everolimus
  • Anti-Cancer Everolimus Purity Everolimus Powder Raw Powder Everolimus
  • Anti-Cancer Everolimus Purity Everolimus Powder Raw Powder Everolimus
  • Anti-Cancer Everolimus Purity Everolimus Powder Raw Powder Everolimus
  • Anti-Cancer Everolimus Purity Everolimus Powder Raw Powder Everolimus
Find Similar Products
  • Overview
  • Product Description
  • Product Details
  • Application&Function
  • Specification
Overview

Basic Info.

Model NO.
D-sung-Everolimus
Certification
GMP, HSE, ISO 9001, USP, BP
Suitable for
Elderly, Adult
State
Powder
Purity
>99%
Product Name
Everolimus
Name
Everolimus Powder
Appearance
White Powder
Grade
Pharmaceutical Grade
Color
White Color
Assay
HPLC 99%
Application
Pharmaceutical;Immunosuppressant
Specific
COA
Test Method
HPLC
Shelf Life
2 Years
CAS No.
159351-69-6
Mf
C53h83no14
MW
958.24
Density
1.18
Boiling Point
998.7 °c at 760 Mmhg
Transport Package
Negotiable
Specification
99%
Trademark
D-sung
Origin
Shaanxi Xi′an
Production Capacity
5000kg/Month

Product Description

Anti-Cancer Everolimus Purity Everolimus Powder Raw Powder Everolimus
Anti-Cancer Everolimus Purity Everolimus powder Raw Powder Everolimus
Product Description
Anti-Cancer Everolimus Purity Everolimus Powder Raw Powder EverolimusAnti-Cancer Everolimus Purity Everolimus Powder Raw Powder Everolimus
Product Details
Anti-Cancer Everolimus Purity Everolimus Powder Raw Powder Everolimus
Product name Everolimus
Cas number 159351-69-6
Appearance White powder
MF C53H83NO14
MW 958.24
Everolimus, an orally adminstered rapamycin analog, has recently been approved by the FDA for treatment of renal cell carcinoma (RCC) refractory to inhibitors of vascular endothelial receptor signaling. Everolimus significantly increased progression-free survival (median PFS for the everolimus treated group was 4.0 months versus 1.9 months for the placebo group), although tumor regressions were observed only infrequently. While the target for everolimus, (the serine/threonine kinase mTOR) is well established, the mechanism by which this agent retards tumor growth is not well defined. Further, biomarkers that predict tumor sensitivity are still elusive. The mechanism of action, preclinical antitumor activity, and clinical activity of everolimus against RCC are reviewed. 
Everolimus is a medication used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.
Everolimus is a macrolide derived from rapamycin (sc-3504) with immunosuppressant properties shown to inhibit cell proliferation induced. Macrolides belong to a group of antibiotics that bind to the 50S ribosomal subunit and inhibit protein synthesis. Studies indicate that everolimus is a mTOR (FRAP) inhibitor that displays high affinity toward the intracellular receptor FKBP12. Additionally, the Everolimus-FKBP12 complex decreases the activity of the S6K1 and 4EBP by binding to FRAP.
Application&Function
Anti-Cancer Everolimus Purity Everolimus Powder Raw Powder EverolimusEverolimus, an orally adminstered rapamycin analog, has recently been approved by the FDA for treatment of renal cell carcinoma (RCC) refractory to inhibitors of vascular endothelial receptor signaling. Everolimus significantly increased progression-free survival (median PFS for the everolimus treated group was 4.0 months versus 1.9 months for the placebo group), although tumor regressions were observed only infrequently. While the target for everolimus, (the serine/threonine kinase mTOR) is well established, the mechanism by which this agent retards tumor growth is not well defined. Further, biomarkers that predict tumor sensitivity are still elusive. The mechanism of action, preclinical antitumor activity, and clinical activity of everolimus against RCC are reviewed. 
Everolimus is a medication used as an immunosuppressant to prevent rejection of organ transplants and in the treatment of renal cell cancer and other tumours. Much research has also been conducted on everolimus and other mTOR inhibitors as targeted therapy for use in a number of cancers.
Specification
Anti-Cancer Everolimus Purity Everolimus Powder Raw Powder EverolimusAnti-Cancer Everolimus Purity Everolimus Powder Raw Powder EverolimusAnti-Cancer Everolimus Purity Everolimus Powder Raw Powder Everolimus
Anti-Cancer Everolimus Purity Everolimus Powder Raw Powder EverolimusAnti-Cancer Everolimus Purity Everolimus Powder Raw Powder EverolimusAnti-Cancer Everolimus Purity Everolimus Powder Raw Powder Everolimus
Anti-Cancer Everolimus Purity Everolimus Powder Raw Powder Everolimus
 

Send your message to this supplier

*From:
*To:
*Message:

Enter between 20 to 4,000 characters.

This is not what you are looking for? Post a Sourcing Request Now
Contact Supplier